[1]
|
Liu, X., Yu, C., Bi, Y. and Zhang, Z.J. (2019) Trends and Age-Period-Cohort Effect on Incidence and Mortality of Prostate Cancer from 1990 to 2017 in China. Public Health, 172, 70-80. https://doi.org/10.1016/j.puhe.2019.04.016
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Sta-tistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[3]
|
中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组. 前列腺癌骨转移多学科诊疗专家共识(2020版) [J]. 肿瘤防治研究, 2020, 47(7): 479-486.
|
[4]
|
Zhong, Y., Valderrama, A., Yao, J., Donga, P., Bilir, P. and Neumann, P.J. (2018) Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients. Value in Health, 21, 304-309.
https://doi.org/10.1016/j.jval.2017.02.008
|
[5]
|
曾浩, 种铁, 贺大林, 等. 去势抵抗性前列腺癌最新指南解读——暨中国西部专家共识[J]. 现代泌尿外科杂志, 2017, 22(2): 85-94.
|
[6]
|
Cattrini, C., Castro, E., Lozano, R., et al. (2019) Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers, 11, Article No. 1355. https://doi.org/10.3390/cancers11091355
|
[7]
|
Zheng, R., Zhang, S., Zeng, H., et al. (2022) Cancer Incidence and Mortality in China, 2016. Journal of the National Cancer Center, 2, 1-9. https://doi.org/10.1016/j.jncc.2022.02.002
|
[8]
|
Body, J.-J., von Moos, R., Rider, A., et al. (2019) A Real-World Study Assessing the Use of Bone-Targeted Agents and Their Impact on Bone Metastases in Patients with Prostate Can-cer Treated in Clinical Practice in Europe. Journal of Bone Oncology, 14, Article ID: 100212. https://doi.org/10.1016/j.jbo.2018.100212
|
[9]
|
Wong, K.W., Ma, W.K., Wong, C.W., et al. (2016) Impact of Skel-etal-Related Events on Survival in Patients with Metastatic Prostate Cancer Prescribed Androgen Deprivation Therapy. Hong Kong Medical Journal, 22, 106-115.
https://doi.org/10.12809/hkmj144449
|
[10]
|
Coleman, R., Body, J.J., Aapro, M., Hadji, P. and Herrstedt, J. (2014) Bone Health in Cancer Patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 25, III124-III137. https://doi.org/10.1093/annonc/mdu103
|
[11]
|
Coleman, R., Hadji, P., Body, J.J., et al. (2020) Bone Health in Can-cer: ESMO Clinical Practice Guidelines. Annals of Oncology, 31, 1650-1663. https://doi.org/10.1016/j.annonc.2020.07.019
|
[12]
|
中国抗癌协会泌尿男生殖系肿瘤专业委员会. 地舒单抗在前列腺癌骨转移患者中的临床应用规范[J]. 肿瘤综合治疗电子杂志, 2021, 7(3): 17-21.
|
[13]
|
Boyce, B.F. and Xing, L. (2007) Biology of RANK, RANKL, and Osteoprotegerin. Arthritis Research & Therapy, 9, Article No. S1. https://doi.org/10.1186/ar2165
|
[14]
|
Baron, R., Ferrari, S. and Russell, R.G. (2011) Denosumab and Bisphospho-nates: Different Mechanisms of Action and Effects. Bone, 48, 677-692. https://doi.org/10.1016/j.bone.2010.11.020
|
[15]
|
de Groot, A.F., Appelman-Dijkstra, N.M., van der Burg, S.H. and Kroep, J.R. (2018) The Anti-Tumor Effect of RANKL Inhibition in Malignant Solid Tumors—A Systematic Review. Cancer Treatment Reviews, 62, 18-28.
https://doi.org/10.1016/j.ctrv.2017.10.010
|
[16]
|
Smith, M.R., Saad, F., Coleman, R., et al. (2012) Denosumab and Bone-Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer: Results of a Phase 3, Randomised, Placebo-Controlled Trial. Lancet, 379, 39-46.
https://doi.org/10.1016/S0140-6736(11)61226-9
|
[17]
|
Ahern, E., Smyth, M.J., Dougall, W.C. and Teng, M.W.L. (2018) Roles of the RANKL-RANK Axis in Antitumour Immunity—Implications for Therapy. Nature Reviews Clinical Oncology, 15, 676-693.
https://doi.org/10.1038/s41571-018-0095-y
|
[18]
|
Gómez-Aleza, C., Nguyen, B., Yoldi, G., et al. (2020) Inhibition of RANK Signaling in Breast Cancer Induces an Anti-Tumor Immune Response Orchestrated by CD8+ T Cells. Nature Communications, 11, Article No. 6335.
https://doi.org/10.1038/s41467-020-20138-8
|
[19]
|
Zhang, X. (2019) Interactions between Cancer Cells and Bone Microenvironment Promote Bone Metastasis in Prostate Cancer. Cancer Communications, 39, Article No. 76. https://doi.org/10.1186/s40880-019-0425-1
|
[20]
|
Bhowmik, D., Song, X., Intorcia, M., Gray, S. and Shi, N. (2019) Examination of Burden of Skeletal-Related Events in Patients Naive to Denosumab and Intravenous Bisphosphonate Therapy in Bone Metastases from Solid Tumors Population. Current Medical Research and Opinion, 35, 513-523. https://doi.org/10.1080/03007995.2018.1532884
|
[21]
|
中国抗癌协会泌尿男生殖系统肿瘤专业委员会. 前列腺癌骨转移和骨相关疾病临床诊疗专家共识(2021版) [J]. 中华肿瘤杂志, 2021, 43(10): 1016-1026.
|
[22]
|
郭卫. 乳腺癌骨转移临床诊疗专家共识[J]. 中国肿瘤临床, 2022, 49(13): 660-669.
|
[23]
|
Fizazi, K., Carducci, M., Smith, M., et al. (2011) Denosumab versus Zoledronic Acid for Treatment of Bone Metastases in Men with Castration-Resistant Pros-tate Cancer: A Randomised, Double-Blind Study. Lancet, 377, 813-822.
https://doi.org/10.1016/S0140-6736(10)62344-6
|
[24]
|
Zhao, H., Han, K.-L., Wang, Z.-Y., et al. (2011) Value of C-Telopeptide-Cross-Linked Type I Collagen, Osteocalcin, Bone-Specific Alkaline Phosphatase and Procollagen Type I N-Terminal Propeptide in the Diagnosis and Prognosis of Bone Metastasis in Patients with Malignant Tumors. Medical Science Monitor, 17, CR626-CR633.
https://doi.org/10.12659/MSM.882047
|
[25]
|
Gibiansky, L., Sutjandra, L., Doshi, S., et al. (2012) Population Phar-macokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours. Clinical Pharmacokinetics, 51, 247-260.
https://doi.org/10.2165/11598090-000000000-00000
|
[26]
|
夏维波, 廖二元, 章振林, 等. 补钙和维生素D对骨骼健康的必要性[J]. 中华骨质疏松和骨矿盐疾病杂志, 2018, 11(1): 1674-2591.
|